Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Patent
1987-04-30
1992-06-16
Schain, Howard E.
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
424 854, A61K 3766
Patent
active
051223724
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD OF INVENTION
This invention relates to the immunotherapeutic treatment of allergies. More particularly, this invention relates to a process for suppressing a mammal's allergic responses to allergens by means of increasing the body's level of gamma interferon. According to this invention, natural or recombinant gamma interferons are used to suppress the allergic responses in a mammal.
BACKGROUND ART
The mechanisms involved in the induction and control of the allergic response are not completely understood. The allergic response is known to be effected by antibody-mediated (immediate-type) hypersensitivity, cell-mediated (delayed-type) hypersensitivity, or both.
The antibody which is largely responsible for immediate type hypersensitivity reactions is immunoglobulin E ("IgE"). IgE antibodies bind to the membranes of mast cells in skin or to basophils, specific membrane receptors that recognize and bind the IgE molecule. The binding affinity of these classes of receptors for IgE is very high. A. Nisonoff, Molecular Immunology, p. 55 (1982).
After the IgE antibody is bound to the cell receptor on the mast cell or basophil, an allergen binds to two or more IgE antibodies, causing the mast cells or basophils to release numerous granules. These granules contain the mediators of immediate hypersensitivity. These mediators have extremely potent contractile effects on the smaller airways of the respiratory tract. In mice and rats, serotonin is the principal mediator. In humans, histamine is the most important mediator of immediate hypersensitivity. SRS-A (Slow Reacting Substance of Anaphylaxis) and ECF-A (Eosinophil Chemotactic Factor) are other mediators.
The symptoms of allergies include sinusitis, rhinitis, hives, headaches, post-nasal drip, coughing, sneezing, respiratory difficulties, sore throats, allergic conjunctivitis, tightness in throat and chest, and loss of voice. In extreme cases the allergic response may cause fetal anaphylactic shock. The sneezing and respiratory difficulties are brought on by contractions of smooth muscle of the respiratory tract. The other symptoms are brought on by the inflammation caused by increased vascular permeability and the attraction of leukocytes.
Examples of antibody-mediated hypersensitivity are hay fever, asthma, food allergies and hives. This type of allergy is called atopy and it is characterized by sensitivity without prior exposure to the allergen causative agent. Delayed-type hypersensitivity is mediated by T-cells. Examples of cell-mediated hypersensitivity include allergic contact dermatitis, allergies to drugs, and a number of autoimmune diseases.
Typically, allergies are treated by a variety of drugs aimed at counteracting the symptoms of an allergic reaction. However, these prior treatments are useful only on a short term basis, and often have adverse or disadvantageous and unwanted side effects. For example, antihistamines are often used to alleviate temporarily the general discomfort caused by histamine release. Such drugs, however, cause drowsiness and therefore are not recommended for use during working hours. Corticosteroids are also used to treat severe allergic reactions. However, these compounds immunosuppress the patient and thereby increase his susceptibility to infectious disease. Inhaled salbutamol (known as albuterol in the United Sates) is commonly used by asthma patients. However, like other sympathomimetic agents, salbutamol can have side reactions such as hypertension, angina, vomiting, vertigo, and insomnia.
In view of the disadvantages of such prior allergy treatments, conventional means for treating allergies remain disappointing to the patient, as well as to the clinician. Therefore, the need exists for a process which avoids these disadvantages and provides effective treatment for allergies.
DISCLOSURE OF THE INVENTION
The present invention solves the problems referred to above by providing a process for suppressing the allergic responses of a mammal by supplementing the body's level of gamma interferon. Advantageo
REFERENCES:
patent: 4289690 (1981-09-01), Pesika
patent: 4314935 (1982-02-01), Uemura
patent: 4376821 (1983-03-01), Braude
patent: 4376822 (1983-03-01), Braude
patent: 4382027 (1983-05-01), Braude
patent: 4681930 (1987-07-01), Kung et al.
W. R. Benjamin et al., "Production of Immune Interferon by an Interleukin 2-Independent Murine T Cell Line," Proc. Natl. Acad. Sci. USA, 79, pp. 5379-5383 (1982).
M. De Lay et al., "Interferon Induced in Human Leukocytes by Mitogens: Production Partial Purification and Characterizatikn," Eur. J. Immunol., 10, pp. 877-883 (1980).
R. Derynck et al., "Expression of the Human Interferon-Gamma CDNA in Yeast," Nucleic Acids Research, 11, pp. 1819-1837 (1983).
R. Devos et al., "Isolation and Characterization of IFN-Gamma MRNA Derived from Mitogen-Induced Human Splenocytes," J. Interferon Res., 2, pp. 409-420 (1982).
R. Derynck et al., "Human Interferon Gamma is Encoded by a Single Class of MRNA", Nucleic Acids Research, 10, pp. 3605-3613 (1982).
R. Devos et al., "In Vitro Translation and Characterization of Human IFN-Gamma MRNA", J. Clin. Hematol. Oncol., 11(4), p. 114 (1981).
R. Devos et al., "Molecular Cloning of Human Immune Interferon CDNA and its Expression in Eukaryotic Cells," Nucleic Acids Research, 10(8), pp. 2487-2501 (1982).
F. Dianzani et al., "Human Immune Interferon: Induction in Lymphoid Cells by a Calcium Ionophore", Infection and Immunity, 29, pp. 561-563 (1980).
N. B. Finier et al., "Physiological and Defective Production of Interferon in Man", Interferon, 4, pp. 147-154 (1985).
G. W. Fishbein, "Schering-Plough Summarizes Recent Gains in Biotechnology," Genet. Eng. Lett., 4(12), p. 3 (1984).
Jaffe et al., "Complications of Co-Trimoxazole in Therapy of Aids-Associated Pneumocysits Carinii Pneumonia in Homosexual Men", Lancet, III, pp. 1109-1111 (1983).
H. W. Murray et al., "Impaired Production of Lymphokines and Immune (Gamma) Interferon in the Acquired Immuno-Deficiency Syndrome", N. England J. Med., 310, pp. 883-889 (1984).
Naray-Fejes-Toth et al., "Recombinant Human Immune Interferon Induces Increased IGE Receptor Expression on the Human Monocyte Cell Line U-937," J. Immunol., 133(4), pp. 1914-1919 (1984).
J. O'Malley, "Affinity Chromatography of Human Immune Interferon", Methods in Enxymology, 78, pp. 540-545 (1981).
J. K. A. Nicholson et al., "Immunoregulatory Subsets of the T Helper and T Suppressor Cell Populations in Homosexual Men with Chronic Unexplained Lymphadenopathy", J. Clin. Invest., 73, pp. 191-201 (1984).
G. H. Reem et al., "Gamma Interferon Induction in Human Thymocytes Activated by Lectins and B Cell Lines", Infection and Immunity, 37, pp. 216-221 (1982).
A. Rubinstein et al., "Acquired Immunodeficiency Syndrome with Reversed T4/T8 Ratios in Infants Born to Promiscuous Drug-Addicted Mothers", JAMA, 249, pp. 2350-2356 (1983).
G. B. Scott et al., "Acquired Immundeficiency Syndrome in Infanis", N. Engl. J. Med., 310, pp. 76-81 (1984).
P. A. Thomas et al., "Unexplained Immunodeficiency in Children. A Surveillance Report", JAMA, 252, pp. 639-644 (1984).
Y. K. Yip et al., "Partial Purification and Characterization of Human Gamma (Immune) Interferon", Proc. Natl. Acad. Sci. USA, 78, pp. 1601-1605 (1981).
Parkin Jacqueline M.
Pinching Anthony J.
Biogen Inc.
Haley, Jr. James F.
Koh Choon Park
McDonell Leslie A.
Schain Howard E.
LandOfFree
Process for treatment of allergies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for treatment of allergies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for treatment of allergies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1752676